BCL2 and B-cell chronic lymphocytic leukemia: A recent study suggested that BTK and BCL2 inhibitors may modulate ferroptosis susceptibility in patients with lymphoid malignancies.16 While ibrutinib has broad effects on CLL cell signaling17 and metabolism,18 its effect on ferroptosis induction is unknown.